Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICTIVE 303: Self-Titration of Insulin Detemir in T2DM
NCT00264901Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2005
- Primary completion
- Nov 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin detemir in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to end of treatment at 26 weeks. Started Oct 2005; status: completed.
02
Drugs
insulin detemir
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00264901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264901.